brompheniramine maleate; pseudoephedrine hydrochloride
EFIDAC 24 PSEUDOEPHEDRINE HYDROCHLORIDE/BROMPHENIRAMINE MALEATE (brompheniramine maleate; pseudoephedrine hydrochloride). Approved for nasal congestion due to the common cold, hay fever, other upper respiratory allergies temporarily relieves these symptoms due to hay fever (allergic rhinitis) runny nose itchy and 2 more indications. First approved in 1996.
Drug data last refreshed 15h ago · AI intelligence enriched 2w ago
EFIDAC 24 is an oral extended-release combination tablet containing brompheniramine maleate (first-generation antihistamine) and pseudoephedrine hydrochloride (nasal decongestant). It treats nasal congestion, hay fever, and upper respiratory allergies by blocking histamine receptors and causing vasoconstriction of nasal blood vessels. The product provides symptomatic relief of allergic rhinitis symptoms including runny nose, itching, watery eyes, sneezing, and nasal congestion.
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity); brand team focus shifting toward life-cycle management and potential transition planning.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on EFIDAC 24 offers limited growth trajectory; roles focus on managing declining market share, optimizing profitability, and potential brand transition or divestment. This is a maintenance-mode position suited for professionals seeking stability over innovation or those with portfolio management/turnaround expertise.